Plans Couldn’t Deny Drugs Over Accelerated Approval

Summary#

A-5789, titled “Prohibits denial of health benefits coverage for prescription drugs based on accelerated FDA approval,” would add a rule to New Jersey law supplementing P.L.1997, c.192. Its stated goal is to prevent health plans from excluding, restricting, or delaying drug coverage because the drug received FDA accelerated approval. The bill is introduced and is not law; if enacted, it would take effect 120 days later and apply to contracts entered into or renewed after that date.

  • The rule would apply to carriers offering health plans in New Jersey that cover pharmacy services, prescription drugs, or participation in a prescription drug plan.
  • Carriers could not use a drug’s accelerated-approval status as a basis to exclude, restrict, or delay coverage. This includes basing a medical-necessity decision on that status.
  • “Carrier” includes insurance companies, health service, hospital service and medical service corporations, health maintenance organizations, and the State and School Employees’ Health Benefits Programs.
  • The bill does not require a plan to cover every prescription drug or guarantee coverage when a carrier has another basis for denying or limiting it.

What it means for you#

  • People with health coverage: If your plan is covered by the bill, the carrier could not deny, restrict, or delay a drug’s coverage because it received FDA accelerated approval. The bill does not prevent decisions based on other grounds.
  • State and school employees: The State Health Benefits Program and School Employees’ Health Benefits Program are included in the definition of carrier.
  • Carriers and health plans: They would have to comply for contracts entered into or renewed after the effective date.
  • General public: The bill would not change FDA approval rules or create a new appeals process or front-line service.

Money#

No publicly available information gives a cost estimate.

  • The bill would impose a coverage rule on carriers, including the two employee benefit programs, but gives no estimate of compliance costs or effects on premiums or public spending.

What is unclear#

  • The supplied material does not include P.L.1997, c.192, so it is not possible to verify how this rule would compare with current law.
  • The bill does not define what it means for a coverage decision to be “based on” accelerated approval.
  • It does not set out coverage review rules, timelines, appeals, or reporting requirements.
  • The bill does not say how this restriction would interact with other coverage rules or plan terms.

Case for#

  • The bill would bar one specific reason for denying, restricting, or delaying coverage: that a drug received FDA accelerated approval.
  • A possible argument for the rule is that coverage decisions should not turn on the approval pathway alone, including when a carrier makes a medical-necessity determination.
  • The bill applies the same stated restriction to the listed carriers, including the state and school employee programs.

Case against#

  • The bill limits carriers’ ability to use accelerated-approval status in coverage decisions, but does not set out a replacement review standard.
  • It is unclear how the rule would affect coverage decisions when accelerated-approval status is considered alongside other factors.
  • The bill provides no information about possible costs to plans, public programs, or people paying premiums.